Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit

Nachrichtenquelle: globenewswire
30.10.2020, 12:00  |  131   |   |   

- Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes

- Potentially increasing safety and efficacy in Freeline’s AAV delivery model

LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced new data on analytical technologies for determining the proportion of Adeno-associated viruses (AAV) capsids containing full-length vector genomes will be presented at the 12th Annual Protein and Antibody Engineering Summit (PEGS), 9 – 13 November 2020.

Freeline will present updated data on the use of analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes, including the use of a panel of assays and combination of methodologies to fully characterise the AAV product. The ‘full-to-empty’ ratio discussed is an important quality attribute for AAVs with potential impact on safety and efficacy.

“We are pleased to report additional data on analytical technologies,” said Theresa Heggie, CEO of Freeline Therapeutics. “This announcement comes in the final quarter of a pivotal year for Freeline, with a strengthened balance sheet following the successful launch of our IPO, continued progress in our clinical programmes in Haemophilia B and Fabry Disease, as well as advancements in our preclinical programmes in Gaucher Disease and Haemophilia A. It has always been our ambition to produce the best-in-class capsid, and these technologies will allow us to potentially increase safety and efficacy across our platform which will benefit all of our programmes.”

Title: Analytical Technologies for Determining the Proportion of AAV Capsids Containing Full-Length Vector Genomes
Presenter: Sonya Schermann, Director of Analytical Development at Freeline

About Freeline
Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.

Seite 1 von 3
Freeline Therapeutics Holdings Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit - Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes - Potentially increasing safety and efficacy in Freeline’s AAV delivery model LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) - …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel